Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Escalated radiation dose alone vs. concurrent chemoradiation for locally advanced and unresectable rectal cancers: results from phase II randomized study.

Engineer R, Mohandas KM, Shukla PJ, Shrikhande SV, Mahantshetty U, Chopra S, Goel M, Mehta S, Patil P, Ramadwar M, Deodhar K, Arya S, Shrivastava SK.

Int J Colorectal Dis. 2013 Jul;28(7):959-66. doi: 10.1007/s00384-012-1630-4. Epub 2013 Jan 29.

PMID:
23358929
2.

Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.

Valentini V, Morganti AG, Gambacorta MA, Mohiuddin M, Doglietto GB, Coco C, De Paoli A, Rossi C, Di Russo A, Valvo F, Bolzicco G, Dalla Palma M; Study Group for Therapies of Rectal Malignancies (STORM).

Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1129-39. Epub 2006 Jan 18.

PMID:
16414206
3.

Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer.

Mohiuddin M, Paulus R, Mitchell E, Hanna N, Yuen A, Nichols R, Yalavarthi S, Hayostek C, Willett C.

Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):523-8. doi: 10.1016/j.ijrobp.2013.02.020. Epub 2013 Mar 29.

4.

CAPIRI-IMRT: a phase II study of concurrent capecitabine and irinotecan with intensity-modulated radiation therapy for the treatment of recurrent rectal cancer.

Cai G, Zhu J, Palmer JD, Xu Y, Hu W, Gu W, Cai S, Zhang Z.

Radiat Oncol. 2015 Feb 28;10:57. doi: 10.1186/s13014-015-0360-5.

5.

Can increasing the dose of radiation by HDR brachytherapy boost following pre operative chemoradiotherapy for advanced rectal cancer improve surgical outcomes?

Sun Myint A, Mukhopadhyay T, Ramani VS, Perkins K, Snee AJ, Jelley F, Wong H, Lee CD.

Colorectal Dis. 2010 Aug;12 Suppl 2:30-6. doi: 10.1111/j.1463-1318.2010.02322.x.

PMID:
20618365
6.

T4 rectal cancer treated with preoperative chemoradiation to the posterior pelvis followed by multivisceral resection: patterns of failure and limitations of treatment.

Sanfilippo NJ, Crane CH, Skibber J, Feig B, Abbruzzese JL, Curley S, Vauthey JN, Ellis LM, Hoff P, Wolff RA, Brown TD, Cleary K, Wong A, Phan T, Janjan NA.

Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):176-83.

PMID:
11516868
7.

Extensive surgery after high-dose preoperative chemoradiotherapy for locally advanced recurrent rectal cancer.

Rödel C, Grabenbauer GG, Matzel KE, Schick C, Fietkau R, Papadopoulos T, Martus P, Hohenberger W, Sauer R.

Dis Colon Rectum. 2000 Mar;43(3):312-9.

PMID:
10733111
8.

Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.

Fernández-Martos C, Pericay C, Aparicio J, Salud A, Safont M, Massuti B, Vera R, Escudero P, Maurel J, Marcuello E, Mengual JL, Saigi E, Estevan R, Mira M, Polo S, Hernandez A, Gallen M, Arias F, Serra J, Alonso V.

J Clin Oncol. 2010 Feb 10;28(5):859-65. doi: 10.1200/JCO.2009.25.8541. Epub 2010 Jan 11.

PMID:
20065174
9.

High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with non-resectable locally advanced rectal cancer (LARC): a phase I trial.

Vestermark LW, Jensen HA, Pfeiffer P.

Acta Oncol. 2012 Mar;51(3):311-7. doi: 10.3109/0284186X.2011.652740. Epub 2012 Jan 17.

PMID:
22248062
10.

Concurrent Chemoradiation with Concomitant Boost in Locally Advanced Rectal Cancer: A Phase II Study.

Picardi V, Deodato F, Guido A, Giaccherini L, Macchia G, Gambacorta MA, Arcelli A, Farioli A, Cellini F, Cuicchi D, DI Fabio F, Poggioli G, Ardizzoni A, Frezza G, Cilla S, Caravatta L, Valentini V, Fuccio L, Morganti AG.

Anticancer Res. 2016 Aug;36(8):4081-7.

PMID:
27466517
11.

Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study.

Zhu J, Liu F, Gu W, Lian P, Sheng W, Xu J, Cai G, Shi D, Cai S, Zhang Z.

Radiat Oncol. 2014 Mar 7;9:70. doi: 10.1186/1748-717X-9-70.

12.

A phase I/II trial of three-dimensionally planned concurrent boost radiotherapy and protracted venous infusion of 5-FU chemotherapy for locally advanced rectal carcinoma.

Myerson RJ, Valentini V, Birnbaum EH, Cellini N, Coco C, Fleshman JW, Gambacorta MA, Genovesi D, Kodner IJ, Picus J, Ratkin GA, Read TE.

Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1299-308.

PMID:
11483342
13.

A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma.

Zhu J, Gu W, Lian P, Sheng W, Cai G, Shi D, Cai S, Zhang Z.

Radiat Oncol. 2013 May 29;8:130. doi: 10.1186/1748-717X-8-130.

14.

Phase I dose escalating trial of hyperfractionated pre-operative chemoradiation for locally advanced rectal cancer.

Movsas B, Hanlon AL, Lanciano R, Scher RM, Weiner LM, Sigurdson ER, Hoffman JP, Eisenberg BL, Cooper HS, Provins S, Coia LR.

Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):43-50.

PMID:
9747818
15.

Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer.

Wong SJ, Winter K, Meropol NJ, Anne PR, Kachnic L, Rashid A, Watson JC, Mitchell E, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG.

Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1367-75. doi: 10.1016/j.ijrobp.2011.05.027. Epub 2011 Jul 19.

16.

Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer.

Velenik V, Oblak I, Anderluh F.

Radiat Oncol. 2010 Sep 29;5:88. doi: 10.1186/1748-717X-5-88.

17.

A randomized controlled pilot study to compare capecitabine-oxaliplatin with 5-FU-leucovorin as neoadjuvant concurrent chemoradiation in locally advanced adenocarcinoma of rectum.

Saha A, Ghosh SK, Roy C, Saha ML, Choudhury KB, Chatterjee K.

J Cancer Res Ther. 2015 Jan-Mar;11(1):88-93. doi: 10.4103/0973-1482.150341.

18.

Chemoradiation with or without intraoperative radiation therapy in patients with locally recurrent rectal carcinoma: prognostic factors and long term outcome.

Valentini V, Morganti AG, De Franco A, Coco C, Ratto C, Battista Doglietto G, Trodella L, Ziccarelli L, Picciocchi A, Cellini N.

Cancer. 1999 Dec 15;86(12):2612-24.

PMID:
10594856
19.

Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.

Wong SJ, Moughan J, Meropol NJ, Anne PR, Kachnic LA, Rashid A, Watson JC, Mitchell EP, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG.

Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):116-23. doi: 10.1016/j.ijrobp.2014.09.031. Epub 2014 Nov 5.

20.

Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.

Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, Hofheinz RD, Ghadimi M, Wolff HA, Lang-Welzenbach M, Raab HR, Wittekind C, Ströbel P, Staib L, Wilhelm M, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R, Liersch T; German Rectal Cancer Study Group.

Lancet Oncol. 2015 Aug;16(8):979-89. doi: 10.1016/S1470-2045(15)00159-X. Epub 2015 Jul 15.

PMID:
26189067

Supplemental Content

Support Center